Hemophilia and AAV Gene Therapy: A Market Driver

adicionou um novo artigo Health

2025-09-16 12:09:13 -

Hemophilia is a prime example of a disease driving growth in the Adeno-associated Virus Vector-based Gene Therapy Market. Hemophilia is a genetic bleeding disorder caused by a deficiency in certain clotting factors. Traditional treatment involves frequent injections to replace these factors, which can be a significant burden on patients. AAV gene therapy offers a potentially life-changing...

0 Comentários 0 Compartilhamentos 4 Visualizações